581 related articles for article (PubMed ID: 33215952)
1. Recent advances of immunotherapy for biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
[No Abstract] [Full Text] [Related]
2. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
[No Abstract] [Full Text] [Related]
3. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):343-350. PubMed ID: 33645367
[No Abstract] [Full Text] [Related]
4. Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look.
Ricci AD; Rizzo A; Brandi G
Cancer Control; 2020; 27(3):1073274820948047. PubMed ID: 32806956
[TBL] [Abstract][Full Text] [Related]
5. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapies in clinical development for biliary tract cancer.
Vogel A; Bathon M; Saborowski A
Expert Opin Investig Drugs; 2021 Apr; 30(4):351-363. PubMed ID: 33382361
[No Abstract] [Full Text] [Related]
7. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
Rizzo A; Ricci AD; Brandi G
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab: an investigational agent for the treatment of biliary tract cancer.
Hack SP; Zhu AX
Expert Opin Investig Drugs; 2021 Oct; 30(10):1007-1015. PubMed ID: 34459336
[TBL] [Abstract][Full Text] [Related]
9. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
10. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
11. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!".
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100335. PubMed ID: 33592561
[TBL] [Abstract][Full Text] [Related]
12. Experimental HER2- targeted therapies for biliary tract cancer.
Rizzo A; Ricci AD; Bonucci C; Tober N; Palloni A; Frega G; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):389-399. PubMed ID: 33218269
[No Abstract] [Full Text] [Related]
13. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
[TBL] [Abstract][Full Text] [Related]
14. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
Ciardiello D; Maiorano BA; Parente P; Rodriquenz MG; Latiano TP; Chiarazzo C; Pazienza V; Guerrera LP; Amoruso B; Normanno N; Martini G; Ciardiello F; Martinelli E; Maiello E
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055006
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatment options for advanced biliary tract carcinoma.
Xie C; McGrath NA; Monge Bonilla C; Fu J
J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic Approaches to Biliary Cancer.
Shah UA; Nandikolla AG; Rajdev L
Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
Filippi R; Lombardi P; QuarĂ V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
[No Abstract] [Full Text] [Related]
20. Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers.
Demir T; Moloney C; Mahalingam D
Crit Rev Oncol Hematol; 2024 Jul; 199():104388. PubMed ID: 38754771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]